vs

Side-by-side financial comparison of Chemours Co (CC) and CLOVER HEALTH INVESTMENTS, CORP. (CLOV). Click either name above to swap in a different company.

Chemours Co is the larger business by last-quarter revenue ($1.3B vs $749.2M, roughly 1.8× CLOVER HEALTH INVESTMENTS, CORP.). CLOVER HEALTH INVESTMENTS, CORP. runs the higher net margin — 3.6% vs -3.5%, a 7.2% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (62.0% vs -2.1%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (45.0% CAGR vs -1.2%).

The Chemours Company is an American chemical company that was founded in July 2015 as a spin-off from DuPont. It has its corporate headquarters in Wilmington, Delaware, United States. Chemours is the manufacturer of Teflon, the brand name of polytetrafluoroethylene (PTFE), known for its anti-stick properties. It also produces titanium dioxide and refrigerant gases.

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

CC vs CLOV — Head-to-Head

Bigger by revenue
CC
CC
1.8× larger
CC
$1.3B
$749.2M
CLOV
Growing faster (revenue YoY)
CLOV
CLOV
+64.1% gap
CLOV
62.0%
-2.1%
CC
Higher net margin
CLOV
CLOV
7.2% more per $
CLOV
3.6%
-3.5%
CC
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
45.0%
-1.2%
CC

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CC
CC
CLOV
CLOV
Revenue
$1.3B
$749.2M
Net Profit
$-47.0M
$27.3M
Gross Margin
11.7%
Operating Margin
3.6%
Net Margin
-3.5%
3.6%
Revenue YoY
-2.1%
62.0%
Net Profit YoY
-261.5%
EPS (diluted)
$-0.32
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CC
CC
CLOV
CLOV
Q1 26
$749.2M
Q4 25
$1.3B
$487.7M
Q3 25
$1.5B
$496.6M
Q2 25
$1.6B
$477.6M
Q1 25
$1.4B
$462.3M
Q4 24
$1.4B
$337.0M
Q3 24
$1.5B
$331.0M
Q2 24
$1.6B
$356.3M
Net Profit
CC
CC
CLOV
CLOV
Q1 26
$27.3M
Q4 25
$-47.0M
$-49.3M
Q3 25
$46.0M
$-24.4M
Q2 25
$-380.0M
$-10.6M
Q1 25
$-5.0M
$-1.3M
Q4 24
$-13.0M
$-22.1M
Q3 24
$-32.0M
$-9.2M
Q2 24
$60.0M
$7.4M
Gross Margin
CC
CC
CLOV
CLOV
Q1 26
Q4 25
11.7%
Q3 25
15.6%
Q2 25
17.2%
Q1 25
17.3%
Q4 24
19.4%
Q3 24
19.0%
24.5%
Q2 24
19.8%
30.3%
Operating Margin
CC
CC
CLOV
CLOV
Q1 26
3.6%
Q4 25
-10.1%
Q3 25
2.5%
-4.9%
Q2 25
-15.4%
-2.2%
Q1 25
-0.3%
Q4 24
-0.1%
-6.4%
Q3 24
-2.1%
-2.7%
Q2 24
4.4%
2.0%
Net Margin
CC
CC
CLOV
CLOV
Q1 26
3.6%
Q4 25
-3.5%
-10.1%
Q3 25
3.1%
-4.9%
Q2 25
-23.5%
-2.2%
Q1 25
-0.4%
-0.3%
Q4 24
-1.0%
-6.6%
Q3 24
-2.1%
-2.8%
Q2 24
3.9%
2.1%
EPS (diluted)
CC
CC
CLOV
CLOV
Q1 26
$0.05
Q4 25
$-0.32
Q3 25
$0.31
Q2 25
$-2.53
Q1 25
$-0.03
Q4 24
$-0.07
Q3 24
$-0.22
Q2 24
$0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CC
CC
CLOV
CLOV
Cash + ST InvestmentsLiquidity on hand
$670.0M
$177.6M
Total DebtLower is stronger
$4.1B
Stockholders' EquityBook value
$250.0M
$339.4M
Total Assets
$7.4B
$697.7M
Debt / EquityLower = less leverage
16.40×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CC
CC
CLOV
CLOV
Q1 26
$177.6M
Q4 25
$670.0M
$78.3M
Q3 25
$613.0M
Q2 25
$502.0M
Q1 25
$464.0M
Q4 24
$713.0M
$194.5M
Q3 24
$596.0M
$288.0M
Q2 24
$604.0M
$254.8M
Total Debt
CC
CC
CLOV
CLOV
Q1 26
Q4 25
$4.1B
Q3 25
$4.1B
Q2 25
$4.1B
Q1 25
$4.1B
Q4 24
$4.1B
Q3 24
$4.0B
Q2 24
$4.0B
Stockholders' Equity
CC
CC
CLOV
CLOV
Q1 26
$339.4M
Q4 25
$250.0M
$308.7M
Q3 25
$274.0M
$340.9M
Q2 25
$228.0M
$344.2M
Q1 25
$566.0M
$336.1M
Q4 24
$571.0M
$341.1M
Q3 24
$643.0M
$342.2M
Q2 24
$714.0M
$324.9M
Total Assets
CC
CC
CLOV
CLOV
Q1 26
$697.7M
Q4 25
$7.4B
$541.0M
Q3 25
$7.5B
$559.7M
Q2 25
$7.5B
$575.0M
Q1 25
$7.4B
$583.7M
Q4 24
$7.5B
$580.7M
Q3 24
$7.5B
$653.0M
Q2 24
$7.2B
$674.2M
Debt / Equity
CC
CC
CLOV
CLOV
Q1 26
Q4 25
16.40×
Q3 25
14.96×
Q2 25
17.99×
Q1 25
7.18×
Q4 24
7.11×
Q3 24
6.20×
Q2 24
5.53×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CC
CC
CLOV
CLOV
Operating Cash FlowLast quarter
$137.0M
Free Cash FlowOCF − Capex
$92.0M
FCF MarginFCF / Revenue
6.9%
Capex IntensityCapex / Revenue
3.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$51.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CC
CC
CLOV
CLOV
Q1 26
Q4 25
$137.0M
$-66.9M
Q3 25
$146.0M
$12.1M
Q2 25
$93.0M
$5.4M
Q1 25
$-112.0M
$-16.3M
Q4 24
$138.0M
$34.8M
Q3 24
$139.0M
$50.0M
Q2 24
$-620.0M
$44.8M
Free Cash Flow
CC
CC
CLOV
CLOV
Q1 26
Q4 25
$92.0M
$-69.0M
Q3 25
$105.0M
$11.4M
Q2 25
$50.0M
$4.8M
Q1 25
$-196.0M
$-16.5M
Q4 24
$29.0M
$33.3M
Q3 24
$63.0M
$49.6M
Q2 24
$-693.0M
$44.4M
FCF Margin
CC
CC
CLOV
CLOV
Q1 26
Q4 25
6.9%
-14.1%
Q3 25
7.0%
2.3%
Q2 25
3.1%
1.0%
Q1 25
-14.3%
-3.6%
Q4 24
2.1%
9.9%
Q3 24
4.2%
15.0%
Q2 24
-44.6%
12.5%
Capex Intensity
CC
CC
CLOV
CLOV
Q1 26
Q4 25
3.4%
0.4%
Q3 25
2.7%
0.1%
Q2 25
2.7%
0.1%
Q1 25
6.1%
0.0%
Q4 24
8.0%
0.5%
Q3 24
5.0%
0.1%
Q2 24
4.7%
0.1%
Cash Conversion
CC
CC
CLOV
CLOV
Q1 26
Q4 25
Q3 25
3.17×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
-10.33×
6.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CC
CC

Titanium Technologies$563.0M42%
Thermal And Specialized Solutions$443.0M33%
Advanced Performance Materials$312.0M23%
Other Non-Reportable Segment$12.0M1%

CLOV
CLOV

Segment breakdown not available.

Related Comparisons